University of Alabama Cystic Fibrosis Research Center
Welcome,         Profile    Billing    Logout  
 2 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jacobs, Susan
MAC2v3, NCT03672630: Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease

Active, not recruiting
2/3
474
Canada, US
Azithromycin, Zithromax, Ethambutol, Myambutol, Rifampin, Rifadin
Kevin Winthrop, Patient-Centered Outcomes Research Institute, National Jewish Health, The University of Texas Health Science Center at Tyler, University Health Network, Toronto, New York University, Medical University of South Carolina, Mayo Clinic, Louisiana State University Health Sciences Center in New Orleans, University of California, San Diego, Stanford University, University of Kansas, Vancouver Clinic, University of California, San Francisco, University of Washington, Johns Hopkins University, University of Miami, Emory University, University of Iowa, University of North Carolina, Temple University, Loma Linda University, Columbia University, University of Wisconsin, Madison, Northwell Health, Kaiser Permanente Hawaii, James A. Haley Veterans Administration Hospital
Mycobacterium Avium Complex, Nontuberculous Mycobacterium Infection
10/25
10/25
PTK0796-NTM-20203, NCT04922554: Oral Omadacycline Vs. Placebo in Adults with NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

Completed
2
66
US
Omadacycline Oral Tablet, Nuzyra, Placebo, placebo tablets
Paratek Pharmaceuticals Inc
Mycobacterium Infections, Nontuberculous, Mycobacterium Abscessus Infection, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterial Pulmonary Infection
06/24
07/24
Soloman, George
NCT03506061: Trikafta in Cystic Fibrosis Patients

Completed
2
42
US
Trikafta, ivacaftor, tezacaftor, elexacaftor
Emory University, National Heart, Lung, and Blood Institute (NHLBI), Cystic Fibrosis Foundation, The University of Texas Health Science Center, Houston
Cystic Fibrosis
02/24
02/24
Berman, Gail
Cycle-2-PEF, NCT06215586: Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction

Recruiting
2
240
Europe, Canada, US, RoW
Tovinontrine (CRD-750, Placebo
Cardurion Pharmaceuticals, Inc.
Heart Failure, Heart Failure Preserved Ejection Fraction, Cardiovascular Diseases, Heart Diseases
10/25
10/25
Cycle-1-REF, NCT06215911: A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction

Recruiting
2
400
Europe, Canada, US, RoW
Tovinontrine (CRD-750), Placebo
Cardurion Pharmaceuticals, Inc.
Heart Failure, Heart Failure With Reduced Ejection Fraction, Cardiovascular Diseases, Heart Diseases
10/25
10/25
PTK0796-NTM-20203, NCT04922554: Oral Omadacycline Vs. Placebo in Adults with NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

Completed
2
66
US
Omadacycline Oral Tablet, Nuzyra, Placebo, placebo tablets
Paratek Pharmaceuticals Inc
Mycobacterium Infections, Nontuberculous, Mycobacterium Abscessus Infection, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterial Pulmonary Infection
06/24
07/24
Garcia, Bryan
ICoN-1, NCT06418711: Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

Recruiting
3
234
US
Clofazimine Inhalation Suspension, MNKD-101, Placebo
Mannkind Corporation
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
08/26
12/28

Download Options